Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | GUSB | P08236 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28307269 | 0.87 | SLC6A4 (0.49) | SLC6A4NR3C1NR3C2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28307271 | 0.87 | SLC6A4 (0.49) | SLC6A4NR3C1NR3C2MEN1KMT2A | |
| SCHEMBL24328894 | 0.83 | SLC6A4 (0.50) | SLC6A4NR3C1NR3C2GUSBKMT2A | |
| SCHEMBL4478874 | 0.81 | SLC6A4 (0.53) | SLC6A4NR3C1NR3C2SNCAHTR1A | |
| SCHEMBL31725739 | 0.81 | CTSL (0.58) | NR3C1NR3C2MEN1HCRTR1KMT2A | |
| SCHEMBL4347796 | 0.79 | SLC6A4 (0.57) | SLC6A4SNCAHTR1A | |
| Hydrochloric Acid SCHEMBL28562385 | 0.79 | NR3C1 (0.48) | SLC6A4NR3C1NR3C2KMT2AHTR1A | |
| SCHEMBL24328924 | 0.79 | SMN1; SMN2 (0.60) | SLC6A4NR3C1NR3C2KMT2ASNCA | |
| SCHEMBL30885590 | 0.78 | SLC6A4 (0.68) | SLC6A4NR3C1NR3C2MEN1KMT2A | |
| SCHEMBL28307268 | 0.78 | SLC6A4 (0.68) | SLC6A4NR3C1NR3C2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137733-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | HTR5A, TPH2, IDO2 | SLC6A4 104/4885NR3C1 2280/4885NR3C2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.